Neuronetics Finally Posts a Profit Quarter — and Quietly Stops Talking About Its Strategic Review
Neuronetics has spent years promising a profitability inflection; in Q3 2026 it produced something that resembles one. Total revenue reached roughly $42 million, up 12.5%, gross margin jumped to 52.2% from 45.9%, operating expenses fell 12.6%, and the company swung to $5 million of operating income from a $7.3 million loss a year earlier. Adjusted EBITDA was $1.9 million versus -$4.7 million, and cash from operations and investing turned positive at $0.8 million — the long-promised cash flow from operating milestone, finally delivered rather than guided toward.
The filed numbers corroborate the direction, if not the full magnitude. The latest 10-Q showed gross margin of 51.1%, up 4.5pp year over year, and operating margin of -3.6%, a 17.5pp year-over-year improvement. The tape has noticed: the stock is up 108.5% over the last 90 days, though it remains roughly 90% below its 2018 peak. This is not a sector wave. Global tape leadership remains dominated by tariff, AI-infrastructure, and macro themes; healthcare movers are in oncology and devices like Pulsed Field Ablation, not interventional psychiatry. Neuronetics' move is company-specific execution, which makes the next few quarters a referendum on durability rather than a ride on a theme.
Capital Sales Are the New Engine — and the Old One Is Shrinking
The strongest part of the quarter was NeuroStar capital equipment, which management called a record for system sales. More than half of units sold went out as capital or lease purchases, lifting average selling price and margin. That reflects a deliberate go to market strategy shift toward multisite, national, and enterprise accounts the old high-touch session model could never reach. A recently awarded sole-source agreement with a large national player is the proof point.
We believe that our go to market changes position us well to compete in a broader segment of the market and expect to yield higher overall net growth in 2027 and beyond.
The trade-off is visible in the segment: NeuroStar revenue rose only 1.8% to $15.8 million because session revenue declined as expected. The company insists customers who prefer the traditional NeuroStar capital-versus-sessions arrangement can keep it, and same-customer sessions grew modestly. But the mix is clearly tilting to equipment. “over half of all of our units sold in Q3 were capital or lease units. That was good for ASP. it is also good for gross margin.” — Daniel L. Reuvers, CEO · 2026-11-04 Investors are rewarding the margin today; the open question is whether the recurring session stream that shrinks now becomes a larger hole once the capital comparison base normalizes in 2027.
Greenbrook: Real Profit Engine, Thin Remaining Fruit
Greenbrook revenue rose 20.1% to $26.2 million, and management was explicit that the margin gain came mostly from revenue-cycle management rather than mix. Skypoint, an AI-enabled coding tool, is the visible instrument: “when we deployed Skypoint, just that change in workflow has led to a low double digit improvement in the first month of collections.” — Daniel L. Reuvers, CEO · 2026-11-04 Cleaner cleaner claims show up in the balance sheet too — receivables to revenue fell to 38.4%, down 30.1pp year over year. Faster cash conversion is not a talking point here; it is a line item.
The more consequential change is how Greenbrook acquires patients. After weighing returns, management is shifting part of its consumer ad budget into the field: “Our goal is to add 8 reps to our already in base of 20 that would take us to 28 by sometime in Q1.” — Daniel L. Reuvers, CEO · 2026-11-04 They claim this happens without raising total sales and marketing spend. That is precisely the lever flagged last quarter — “I would expect that we will probably pull and push on some levers, try and rebalance some and balance our spend in the most effective paths and at the expense of some of the others.” — Daniel Reuvers, President and Chief Executive Officer · 2026-08-11 Yet the subtext is an admission: direct-to-consumer traffic arrives less qualified, clogging intake, while referred patients arrive having already failed two medications. Expanding the sales team is a quiet concession that the cheaper channel was not the better one.
Utilization remains the swing factor. Management describes a big range in clinic occupancy, from roughly 25% at the low end to 75% at the top, with intent to lift the bottom quartile. That is where the operating leverage lives. It is also why the rep reallocation matters more than any single cost line.
The Optionality Stack: PTSD, EHR, and COMP360
Three genuinely new items broaden the story. First, a distribution agreement with Wave Neuroscience to integrate its MeRT system with NeuroStar; MeRT received FDA clearance in June for PTSD, and management cites roughly 9 million U.S. adults with PTSD, over 4 million of whom seek treatment. Second, a TMS Journal analysis of more than 6,400 patients found no statistically significant outcome difference for those with treatment gaps, with missing up to 13 days not reducing effectiveness. That is a demand-side unlock: the miss days message gives patients and referring psychiatrists permission to start a seven-week course without treating it as an unbreakable commitment. Third, the first TMS-to-EHR integration links TrackStar with AdvancedMD, deepening the workflow moat and enriching the proprietary dataset. The AMD partnership is small today, but it targets existing AdvancedMD practices that are not yet NeuroStar customer accounts — a clean hunting ground with a differentiated pitch.
The biggest call option remains COMPASS Pathways and the anticipated launch of COMP360 in treatment-resistant depression, with an FDA submission expected within weeks. Greenbrook's 84 Spravato clinics supply a ready REMS-capable footprint, and management plans a hub-and-spoke pilot rather than a national rollout. “We expect we will learn a lot with the introduction.” — Daniel L. Reuvers, CEO · 2026-11-04 But no exclusivity exists. Prior disclosure was blunt: “COMPASS has about seven of these strategic collaborations to help them prepare for commercial readiness, and Greenbrook is one of them.” — Corey Anderson, Chief Technology Officer · 2026-03-17 The opportunity is real; it is simply not proprietary, and the benefit investigation and prior-authorization machinery that makes it plausible is the same infrastructure already built for Spravato.
What Went Unsaid
The most interesting element of this call may be what vanished. In Q1 2026, after an activist letter pushed for a strategic review and possible sale of the TMS business, the CEO said he was looking at the business with fresh eyes: “I'm not wed to a predetermined conclusion, but I'm also not inclined to be impetuous and make sure that I look at the business overall.” — Daniel Reuvers, President and Chief Executive Officer · 2026-05-05 On the Q3 call, the strategic review went unmentioned. So did the U.S. Attorney investigation into pre-acquisition Greenbrook billing practices that dominated the Q4 2025 discussion. Positive EBITDA and positive cash flow may have bought management time and credibility, but silence is not an answer to either question, and the balance sheet is no longer a comfortable cushion — effective net cash sits near -$40 million after a multi-year deterioration from peak levels.
For a $172 million market-cap company whose stock has doubled in 90 days, the setup is binary. The capital pivot is working, Greenbrook is converting billed dollars to cash faster, and the optionality stack — PTSD, EHR, COMP360 — is fuller than at any point in years. But the recurring session base is contracting, the easiest revenue-cycle gains are now behind them, and the strategic-alternatives question has merely been moved offstage. The next two quarters will tell us whether Q3 was the inflection or the high-water mark of a very good cost-cutting quarter.